



June 2021

**Harbour BioMed** **Journal**  
Investor Relations

02142.HK

**HARBOUR**  
BIOMED



# CONTENTS


HBM Overview	01
Company Announcement	02
Company News	03
2021 Virtual Investor Forum	04
BioMed Industry	05
Global Market Overview	06

# HBM (02142.HK)


Overview	
Website--Investor Access	<a href="https://www.harbourbiomed.com/investor">https://www.harbourbiomed.com/investor</a>
Market Cap (05/31, Mil HK\$)	8999.67
Total Share Capital (Mil)	767.89
Circulation Stock (Mil)	767.89

Most HK indices have been showing upward trends in May with the Hang Seng Index (HSI) closing 2.8% higher than the beginning of the month. The Hang Seng Composite Index (HSCI) was up 2.2% and the Hang Seng Healthcare Index was up 7.1%. HBM continued to rise in May, closing 16.97% higher than the beginning of the month.

## HBM Stock Performance – May



## The Hang Seng Composite Index (HSCI) – May





# Company Announcement

---

The company announced updates of the ongoing Batoclimab clinical trial (HBM9161). The MG interim analysis report has been submitted to the China Center for Drug Evaluation (CDE) and has been fully approved to proceed with the phase III pivotal trial. The ITP phase II data has been reviewed by an independent data monitoring committee and confirmed that no safety concerns were identified including lipid test results. The phase Ib/IIa studies in patients with NMOSD remain on track and no additional safety signal have been identified.

---

The company announced first patient dosed in the phase Ib/IIa clinical study of its next generation anti-CTLA-4 antibody (HBM4003) in Australia. The objective of this study is to evaluate the safety, tolerability, PK/PD, and anti-tumor activity of HBM4003 as a single agent in multiple solid tumor types. The part 1 of phase I trial study results have been submitted to European Society of Medical Oncology (ESMO).



# Company News

01

The Capital Group increased its stake in Harbour BioMed. With the increased shares, the stake held by Capital Group reaches 6.1% correspondingly.

02

A deep-dive review on *Tackling COVID-19 with neutralizing monoclonal antibodies* published on Cell proving the broad indication of the neutralizing antibodies including 47D11.

03

Dr. Jingsong Wang was invited to CEIBS (China Europe International Business School) FMBA on the *Golden Age of China Biopharma* panel.

04

Dr. Haiyan Mao was appointed as HBM Vice President and Head of Clinical Operations.

05

HBM announced a strategic cooperation with BioMap (by Baidu), opening a new chapter for AI drug discoveries.

06

HBM and Nankai University have jointly discovered neutralizing antibody SARS-CoV2-2 with novel epitopes.

# 2021 Virtual Investor Forum

## Highly Effective Innovation Engine Drives Value Creation

(HBM HOLDINGS-B: 02142.HK)

Date: 6/17/2021 (Thursday)

Time: 20:00-21:00 CST 08:00-09:30 EST 14:00-15:30 CET

Language: English

### Key Opinion Leader (KOL)



Dr. Frank Grosveld

- Founding Chief Scientific Officer & SAB Member of Harbour BioMed
- Inventor of Harbour Mice®, Harbour's core technology platform
- Professor of Department of Cell Biology & Department of Clinical Genetics at Erasmus University Medical Center
- Fellow of Royal Society & Member of Royal Netherlands Academy of Arts and Sciences



Dr. Robert Kamen

- Independent Non-Executive Director of Harbour BioMed
- SAB Member of Harbour BioMed
- Venture Partner at Third Rock Ventures
- Former Director of Harbour Antibodies
- Former President & Unit Head of Abbott Bioresearch Centre



RSVP




# BioMed Industry

## Market Overview

In May 2021, HSCI closed at 4,580.33 at the end of the month, up 2.19% from the beginning of the month. HSHCI closed at 8009.34 at the end of the month, up 7.06% from the beginning of the month. CESHKB.CSI closed at 15752.12 at the end of the month, up 11.25% from the beginning of the month.

### HK Listing BioMed Companies (18A)



Closing Date: 5/31/2021

Notes: The coordinate axis is scaled with logarithm

# Global Market Overview

Global Market Index			
	Closing Price		
	2021.05.03	2021.05.14	2021.05.31
Dow Jones Industrial Average	34113.23	34382.13	34529.45
NASDAQ Composite	13895.12	13429.98	13748.74
UK FTSE 100	6969.81	7043.61	7022.61
German DAX	15236.47	15416.64	15421.13
France CAC40	6307.90	6385.14	6447.17

HK Market Index			
	Closing Price		
	2021.05.03	2021.05.14	2021.05.31
Hang Seng	28,357.54	28,027.57	29,151.80
Hang Seng Composite	4,482.33	4,364.96	4,580.33
Hang Seng Tech	8,227.89	7,565.31	8,104.35
HS China Enterprise	10,713.00	10,404.95	10,889.12
Hang Seng Healthcare	7,480.99	7,338.63	8,009.34

Global Economic Data			
Country	Related Events	Estimated	Actual
USA	Richmond Fed Manufacturing	19	18
Germany	GfK Consumer Confidence	-5.2	-7
UK	CBI Retail Sales Difference	30	18
EU	Economic Sentiment	11.3	11.5
EU	Final Value of Consumer Confidence	-5.1	-5.1
France	Final GDP Annual Rate of 1Q	1.5%	1.2%

- The initial annual rate of inflation in EU went up to 2% in May, slightly exceeding expectations.
- Canada's first quarter GDP annualized quarterly rate growth rate narrowed to 5.6%.
- US May Markit manufacturing PMI final value rose to 62.1, a record high.



# HARBOUR BIOMED



Harbour BioMed

[ir@harbourbiomed.com](mailto:ir@harbourbiomed.com)

[www.harbourbiomed.com](http://www.harbourbiomed.com)